Drug Patents owned by Secura

1. List of Copiktra drug patents

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(6 years from now)

USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods
Jan, 2029

(5 years from now)

US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(8 years from now)

US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(8 years from now)

Do you want to check out COPIKTRA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 2022-09-24

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

34

United States

10

European Union

9

New Zealand

8

Singapore

7

Japan

7

China

6

Korea, Republic of

6

Ukraine

6

Russia

6

Mexico

5

Australia

5

Israel

4

Canada

4

Malaysia

4

Philippines

4

Brazil

4

South Africa

3

Denmark

3

Spain

3

Hong Kong

3

Taiwan

2

Peru

2

Argentina

1

India

1

Croatia

1

Netherlands

1

Chile

1

Cyprus

1

Portugal

1

Poland

1

Slovenia

1

San Marino

1

Hungary

1

Lithuania

2. List of Farydak drug patents

FARYDAK's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7989494 SECURA Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Jan, 2028

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883842 SECURA Use of HDAC inhibitors for the treatment of myeloma
Jun, 2028

(5 years from now)

Do you want to check out FARYDAK patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 23, 2022

Drugs and Companies using PANOBINOSTAT LACTATE ingredient

Market Authorisation Date: 23 February, 2015

Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone

Dosage: CAPSULE;ORAL

More Information on Dosage

FARYDAK family patents

10

United States

5

Korea, Republic of

5

Japan

4

China

3

European Union

2

Australia

2

Canada

2

Mexico

2

Brazil

2

Taiwan

1

Ecuador

EA

1

EA

1

Israel

1

Denmark

1

Honduras

1

Spain

1

Uruguay

1

Tunisia

1

Peru

1

Malaysia

1

Costa Rica

1

Nicaragua

1

Chile

1

ME

1

Cyprus

1

Portugal

1

Ukraine

1

Philippines

1

Poland

1

Russia

1

Morocco

1

Norway

1

Slovenia

1

Georgia

1

Argentina

1

South Africa

1

San Marino

1

Guatemala

1

Hungary

1

Lithuania

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic